CD2 x CD3 multispecific DARPin T-cell engager - Molecular Partners AG
Latest Information Update: 04 Jul 2025
At a glance
- Originator Molecular Partners AG
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action CD2 antigen stimulants; CD3 antigen stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours